Laboratory Net Income From Continuing Ops vs Operating Income Analysis
LH Stock | USD 237.15 1.28 0.54% |
Laboratory financial indicator trend analysis is infinitely more than just investigating Laboratory recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Laboratory is a good investment. Please check the relationship between Laboratory Net Income From Continuing Ops and its Operating Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Net Income From Continuing Ops vs Operating Income
Net Income From Continuing Ops vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Laboratory Net Income From Continuing Ops account and Operating Income. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Laboratory's Net Income From Continuing Ops and Operating Income is 0.55. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Operating Income in the same time period over historical financial statements of Laboratory of, assuming nothing else is changed. The correlation between historical values of Laboratory's Net Income From Continuing Ops and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Laboratory of are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Net Income From Continuing Ops i.e., Laboratory's Net Income From Continuing Ops and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.55 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Income From Continuing Ops
Operating Income
Operating Income is the amount of profit realized from Laboratory operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Laboratory of is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Laboratory's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Laboratory current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. As of now, Laboratory's Tax Provision is increasing as compared to previous years. The Laboratory's current Enterprise Value is estimated to increase to about 7.8 B, while Selling General Administrative is projected to decrease to under 1.1 B.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.6B | 4.4B | 3.4B | 2.0B | Total Revenue | 16.1B | 14.9B | 12.2B | 12.8B |
Laboratory fundamental ratios Correlations
Click cells to compare fundamentals
Laboratory Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Laboratory fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 98.6M | 98M | 97.5M | 91.6M | 87.6M | 96.0M | |
Total Assets | 18.0B | 20.1B | 20.4B | 20.2B | 16.7B | 17.6B | |
Other Current Liab | 942.4M | 784.2M | 967M | 1.6B | 504.3M | 478.7M | |
Total Current Liabilities | 1.9B | 2.6B | 3.1B | 2.8B | 3.2B | 3.4B | |
Total Stockholder Equity | 7.6B | 9.4B | 10.3B | 10.1B | 7.9B | 8.3B | |
Property Plant And Equipment Net | 2.6B | 2.7B | 2.8B | 3.0B | 2.9B | 3.1B | |
Net Debt | 6.7B | 5.4B | 4.9B | 5.9B | 5.4B | 5.7B | |
Retained Earnings | 7.9B | 9.4B | 10.5B | 10.6B | 7.9B | 8.3B | |
Accounts Payable | 632.3M | 638.9M | 621.3M | 852.2M | 827.5M | 868.9M | |
Cash | 337.5M | 1.3B | 1.5B | 430M | 536.8M | 290.8M | |
Non Current Assets Total | 15.0B | 14.9B | 15.1B | 15.5B | 13.0B | 13.6B | |
Non Currrent Assets Other | 435.4M | 410M | 462.6M | 432.7M | 536.5M | 270.8M | |
Cash And Short Term Investments | 337.5M | 1.3B | 1.5B | 430M | 536.8M | 299.7M | |
Net Receivables | 2.0B | 3.0B | 3.0B | 2.0B | 2.1B | 2.2B | |
Liabilities And Stockholders Equity | 18.0B | 20.1B | 20.4B | 20.2B | 16.7B | 17.6B | |
Non Current Liabilities Total | 7.8B | 7.6B | 7.3B | 7.0B | 5.6B | 3.1B | |
Other Current Assets | 373.7M | 364.8M | 478.1M | 2.4B | 655.3M | 688.1M | |
Other Stockholder Equity | 26.8M | 110.3M | (192M) | (493.2M) | 38.4M | 36.5M | |
Total Liab | 10.5B | 10.7B | 10.1B | 10.1B | 8.8B | 9.3B | |
Total Current Assets | 3.0B | 5.1B | 5.3B | 4.6B | 3.8B | 4.0B | |
Short Long Term Debt Total | 7.1B | 6.8B | 6.3B | 6.3B | 6.0B | 3.0B | |
Intangible Assets | 4.0B | 4.0B | 3.7B | 3.9B | 3.3B | 2.0B | |
Short Term Debt | 621.1M | 774.1M | 396.5M | 471.1M | 1.3B | 1.4B | |
Inventory | 244.7M | 423.2M | 401.4M | 470.6M | 474.6M | 498.3M | |
Property Plant And Equipment Gross | 2.6B | 2.7B | 5.2B | 5.7B | 5.8B | 6.1B | |
Accumulated Other Comprehensive Income | (372.4M) | (161.9M) | (192M) | (493.2M) | (59.3M) | (62.3M) | |
Other Liab | 1.3B | 1.4B | 1.2B | 1.1B | 1.2B | 702.7M | |
Other Assets | 356.5M | 350.9M | 484.2M | 440.3M | 506.3M | 531.7M | |
Long Term Debt | 5.8B | 5.4B | 5.4B | 5.0B | 4.1B | 3.1B | |
Property Plant Equipment | 2.7B | 2.8B | 2.8B | 3.0B | 3.4B | 3.6B | |
Good Will | 7.9B | 7.8B | 8.0B | 8.1B | 6.1B | 4.4B | |
Current Deferred Revenue | 451M | 506.5M | 558.5M | 582.1M | 421.7M | 442.8M | |
Net Tangible Assets | (4.3B) | (2.4B) | (1.4B) | (2.0B) | (1.8B) | (1.9B) | |
Long Term Debt Total | 5.9B | 5.5B | 5.5B | 5.1B | 5.9B | 4.8B |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.05) | Dividend Share 2.88 | Earnings Share 5.28 | Revenue Per Share 151.028 | Quarterly Revenue Growth 0.074 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.